Highlights Vincerx Pharma, Inc.

Equities

VINC

US92731L1061

Market Closed - Nasdaq Other stock markets 01:30:00 17/05/2024 am IST			5-day change	1st Jan Change
0.72 ^USD	-3.73%		-15.29%	-38.98%

26/04	Tech Rally Boosts Exchange-Traded Funds, Equity Futures Pre-Bell Friday	MT
26/04	Vincerx Pharma Prices Public Offering of Shares, Warrants	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tech Rally Boosts Exchange-Traded Funds, Equity Futures Pre-Bell Friday	26/04	MT
Vincerx Pharma Prices Public Offering of Shares, Warrants	26/04	MT
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	09/04	MT
Top Premarket Decliners	09/04	MT
Vincerx Pharma, Inc. Presents Positive Preliminary Phase 1 Data for Vip236 and Updates on Pipeline Progress At the American Association for Cancer Research Annual Meeting 2024	09/04	CI
Vincerx Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03	CI
North American Morning Briefing : Tech in Focus on -2-	25/03	DJ
Vincerx Pharma, Inc. Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma	08/01	CI
Vincerx Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Vincerx Pharma Says US FDA Approved Phase 1 Trial for Potential Acute Myeloid Leukemia Treatment	22/23/22	MT
Vincerx Pharma, Inc. Announces FDA Clearance of IND for VIP943	22/23/22	CI
Vincerx Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/23/07	CI
Vincerx Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Vincerx Pharma, Inc. Presents Preclinical Data of Vip236 Monotherapy Treatment in Pdx and Metastatic Pdx Mouse Models Across Several Tumor Types	17/23/17	CI
Vincerx Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	29/23/29	CI
Vincerx Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	29/23/29	CI
Vincerx Pharma Announces Fda Safe to Proceed Letter for Investigational New Drug Application for Its V3 Small Molecule-Drug Conjugate Vip236	13/22/13	CI
Vincerx Pharma, Inc. Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022	11/22/11	CI
Vincerx Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11	CI
Earnings Flash (VINC) VINCERX PHARMA Reports Q3 Loss $-0.80	11/22/11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vincerx Pharma, Inc.

Equities

VINC

US92731L1061

Highlights

Filters